The Development Status of Chinese Drug Group Purchasing Model and the Exploration of Market-based GPO Path

China Health Insurance ›› 2023, Vol. 0 ›› Issue (3) : 19-25.

China Health Insurance ›› 2023, Vol. 0 ›› Issue (3) : 19-25. DOI: 10.19546/j.issn.1674-3830.2023.3.003
Topics in Focus

The Development Status of Chinese Drug Group Purchasing Model and the Exploration of Market-based GPO Path

Author information +
History +

Abstract

This study adopted research methods such as literature study, comparative study, and interview research. By referring to the experience of American group purchasing, this study analyzed the current situation of the operation of the existing GPO model in China in detail and proposed a development path for exploring market-based GPO in China, taking into account the conditions of China's pharmaceutical industry. The government could first support the development of social GPOs, relying on existing procurement platforms. In addition, the government should continue to improve the operating rules and gradually transit to market-based GPOs when the environment is mature. GPOs should also constantly improve their organizational structure, innovate procurement models, and provide high-quality procurement services. At the same time, GPO industry supervision should be improved to jointly promote the development of GPO, so that procurement is really beneficial to the people.

Key words

drug group purchasing / market-based GPO / socialized GPO / procurement services

Cite this article

Download Citations
The Development Status of Chinese Drug Group Purchasing Model and the Exploration of Market-based GPO Path[J]. China Health Insurance. 2023, 0(3): 19-25 https://doi.org/10.19546/j.issn.1674-3830.2023.3.003

References

[1] 谢金平,王斌,陈缪丰,等.常州市第二批国家药品集中采购政策实施效果研究——基于双组间断时间序列分析[J].中国卫生政策研究,2022,15(05):59-66.
[2] 国务院办公厅.关于完善公立医院药品集中采购工作的指导意见[EB/OL].(2015-02-28)[2023-01-15]. http://www.gov.cn/zhengce/content/2015-02/28/content_9502.htm.
[3] 王莹,焦明丽,姜巍.解构主义视角下美国百年GPO驱动因素、供应链分析及对我国的启示[J].中国卫生经济,2021,40(05):12-15.
[4] 谢金平,张雪瑞,张赫,等.典型发达国家药品采购模式研究及启示[J].卫生经济研究,2022,39(01):64-68.
[5] IBIS World. Group Purchasing Organizations in the US-Market Size2005-2027[EB/OL]. (2021-08-17)[2023-01-15]. https://www.ibisworld.com/industry-statistics/market-size/group-purchasing-organizations-united-states/.
[6] 张志慧. 美国集团采购与药品福利管理模式对比研究[J].中国医疗保险,2021(07):76-80.
[7] 邵蓉,谢金平,蒋蓉.美国集团采购组织分析及对我国药品采购的启示[J].中国卫生政策研究,2014,7(06):35-40.
[8] 丛鹂萱,陈珉惺,邹璇,等.美国集团采购组织核心要素介绍及与深圳模式对比分析[J].中国卫生经济,2019,38(12):113-116.
[9] JING J, JIAMEI X, YUE Y, et al.Group Purchasing Organizations (GPOs) in the US: Development and Reform[J].亚洲社会药学, 2019, 14(3): 100-109.
[10] OPOKU-AGYEMAN W, WEECH-MALDONADO R, UPADHYAY S, et al.Environmental and Organizational Factors Associated with Hospital Use of GPO Services[J]. Hospital Topics, 2020, 98(3): 89-102.
[11] 苏涛,常峰,邵蓉.对美国药品集中采购组织的解析[J].上海药,2011,32(06):295-297.
[12] Government Accountability Office. Group Purchasing Organizations: Federal Oversight and Self-Regulation[EB/OL]. (2012-03-30)[2022-05-05]. https://www.gao.gov/products/gao-12-399r.
[13] 王永利. 深圳药品集采GPO模式值得总结推广[J].中国经贸导刊,2021(10):26-28.

Accesses

Citation

Detail

Sections
Recommended

/